Drug Database
Back to search

Japan· JP-2391008M2044

アプレピタント

A aprepitant product containing アプレピタント, registered in Japan by 沢井製薬, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

On Japan’s NHI price listATC A04AD12

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedアプレピタントATCA04AD12REGISTER NO.JP-2391008M2044PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about アプレピタントAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aprepitant is registered in 17 of 19 countries.

Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 9 of them publish a price we can compare per daily dose
Search aprepitant products by name

Aprepitant · ATC A04AD12

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aprepitant costs, country by country.

Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Aprepitant · price per daily dose (165 mg)

USD · FX 28 Sept 2026

  • US United States$157.48 (acquisition cost)
  • CH Switzerland$73.26
  • FR France$33.15
  • FI Finland$0.40
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
アプレピタント
Manufacturer
沢井製薬
Country
Japan (JP)
ATC code
A04AD12
ATC class
Aprepitant
Defined daily dose
165 mg, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

583 interactions on record for aprepitant.

Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aprepitant against other medicinesHow interaction checks work

Aprepitant · interactions on record

583 records

  • 73 severe
  • 380 moderate
  • 25 minor
  • 104 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • LonafarnibA16AX20severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under A04AD12

Aprepitant, as other registers publish it.

All aprepitant products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e66e1cb8-fa8f-4113-af90-3be8e7080916
GET /v1/drugs/e66e1cb8-fa8f-4113-af90-3be8e7080916?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１２５ｍｇ１カプセル",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2391008M2044",
  "category": "内用薬",
  "price_yen": 942,
  "generic_name": "アプレピタント",
  "product_name_jp": null,
  "therapeutic_class": "2391",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about aprepitant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console